A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|180|1|41-51

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.1, 2018-01, pp. : 41-51

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM‐003 trial for pomalidomide plus low‐dose dexamethasone

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 820-823

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 162, Iss. 2, 2013-07 ,pp. : 202-209

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 3, 2015-08 ,pp. : 336-348

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 60-70

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 52-59

John Wiley & Sons Inc

Access to resources Recommend Favorite